Siglec receptors as new immune checkpoints in cancer
- PMID: 35948467
- DOI: 10.1016/j.mam.2022.101112
Siglec receptors as new immune checkpoints in cancer
Abstract
Cancer immunotherapy in the form of immune checkpoint inhibitors and cellular therapies has improved the treatment and prognosis of many patients. Nevertheless, most cancers are still resistant to currently approved cancer immunotherapies. New approaches and rational combinations are needed to overcome these resistances. There is emerging evidence that Siglec receptors could be regarded as new immune checkpoints and targets for cancer immunotherapy. In this review, we summarize the experimental evidence supporting Siglec receptors as new immune checkpoints in cancer and discuss their mechanisms of action, as well as current efforts to target Siglec receptors and their interactions with sialoglycan Siglec-ligands.
Keywords: Cancer immunotherapy; Immune checkpoint inhibitor; Innate immunity; Monoclonal antibodies; Sialic acid; Sialidase; T cells.
Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of competing interest H.L. received travel grants and consultant fees from BMS and Merck, Sharp and Dohme (MSD). H.L. received research support from BMS and Palleon Pharmaceuticals. H.L. is a scientific advisor of InterVenn and GlycoEra. H.L. is a co-founder of Singenavir Ltd.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
